Last updated on July 2019

Study to Assess Safety Efficacy Pharmacokinetics and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria

Brief description of study

This is a Phase I/II, first-in-human study consisting of 3 sequential parts and an open-label extension (OLE) in which the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single-doses of RO7112689 will be evaluated in healthy volunteers (HV) during Part I, and safety, tolerability, PK, and PD of RO7112689 will be evaluated in participants with PNH during Parts 2, 3, and OLE of the study. Efficacy of RO7112689 will be evaluated in Parts 2 and 3.

Clinical Study Identifier: NCT03157635

Find a site near you

Start Over